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Autonomic nervous system dysfunction and sinonasal
symptoms
Alexander Yao, MRCS (ENT),1 Janet A. Wilson, FRCS (ENT),2 and Stephen L. Ball, Ph.D.3
ABSTRACT
Background: The autonomic nervous system (ANS) richly innervates the nose and paranasal sinuses, and has a significant
role in lower airway diseases, e.g., asthma. Nonetheless, its contribution to sinonasal symptoms is poorly understood. This
review aimed to explore the complex relationship between the ANS and sinonasal symptoms, with reference to systemic diseases
and triggers of ANS dysfunction.
Methods: A review of articles published in English was conducted by searching medical literature databases with the key
words “autonomic nervous system” and (“sinusitis” or “nose” or “otolaryngology”). All identified abstracts were reviewed,
and, from these, relevant published whole articles were selected.
Results: The ANS has a significant role in the pathophysiologic mechanisms that produce sinonasal symptoms. There was
limited evidence that describes the relationship of the ANS in sinonasal disease with systemic conditions, e.g. hypertension.
There was some evidence to support mechanisms related to physical and psychological stressors in this relationship.
Conclusion: The role of ANS dysfunction in sinonasal disease is highly complex. The ANS sits within a web of multiple
factors, including personality and psychological distress, that contribute to sinonasal symptoms. Further research will help to
clarify the etiology of ANS dysfunction and its contribution to common systemic conditions.
(Allergy Rhinol 9:1–9, 2018; doi: 10.1177/2152656718764233)
The autonomic nervous system (ANS) is a phenom-enon in health and disease. Its dysfunction tran-
scends a variety of systemic conditions, including car-
diovascular and lower airway pathologies.1,2 Although
the unified airway hypothesis indicates shared patho-
physiological processes across both the upper and
lower airways,3–5 the role of the ANS in nose and sinus
symptoms is poorly understood. Historically, the ca-
pacity of the nasal vasculature to shrink and engorge in
animals was known in the 1850s and was histologically
characterized as early as the 1950s.6 The important
vasomodulatory effects of autonomic nerves in the
nose were highlighted by Millonig et al.7 in 1950 and
further supported by evidence from cases of autonomic
denervation in patients with nose symptoms. Konno
and Togawa8 described, in 1979, the successful use of a
vidian nerve section to improve symptoms of patients’
allergic rhinitis. However, the transient results and
variable benefits for different symptoms indicate a
more complex relationship between the nose and the
ANS.
It is apparent now that the nose plays an important
role in regulating temperature and in humidifying and
protecting the passage of air that enters the lower
airways via the rich autonomic innervation of nasal
vasculature and nasal glands.9–11 However, the chal-
lenges in developing our understanding of the ANS in
the nose are compounded by the bewildering variety of
tests used to measure ANS function: Valsalva tests,
deep breathing tests, isometric handgrip, cold pressor
tests, orthostatic tests, tilt-table tests, mental arithmetic,
neurotransmitter measurement, sudomotor function
tests, microneurography, and heart rate variability
(HRV) measurement.12
Of these, HRV, as measured through variations be-
tween the R waves of the QRS complex (RR interval),
has become one of the most accepted and popular
tests.13 Low frequency (LF) HRV corresponds to both
sympathetic activity and parasympathetic activity,
whereas high frequency (HF) HRVmainly corresponds
to increased parasympathetic activity. Although the
LF:HF ratio has been suggested as a measure of sym-
pathovagal balance, this remains highly controver-
sial.14 The complexity of the ANS is such that there
usually is no single best test and, therefore, tests are
more often used in combination rather than in isola-
tion. Recently, increasing evidence that indicates that
the characteristic symptoms of sinonasal diseases, in-
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cluding nasal obstruction, rhinorrhea, and facial pres-
sure and/or pain, may be, at least in part, due to
disruption of normal ANS function. Furthermore, si-
nonasal disease has been increasingly linked to chronic
systemic disorders, including cardiovascular dysfunc-
tion, with the possibility that autonomic dysregulation
may underlie these associations.1
This review aims to discuss the most recent literature
regarding the role of the ANS in the pathophysiology
of sinonasal symptoms, including the following: (1)
what is the role of the ANS in the causation of sinona-
sal symptoms; (2) what part does the ANS have in the
association of sinonasal symptoms and systemic dis-
eases; (3) what processes drive ANS dysfunction in
sinonasal symptoms, in particular, is there a relevant
association with physical or psychological stress
states? To conclude the clinical implications of these
questions will be highlighted. The Medline and Em-
base (Elsevier, Amsterdam, the Netherlands) data
bases searches were conducted by using the Medical
Subject Headings key words “autonomic nervous sys-
tem” and (“sinusitis” or “nose” or “otolaryngology”).
WHAT IS THE ROLE OF THE ANS IN THE
CAUSATION OF SINONASAL SYMPTOMS?
Nasal Obstruction
Physical nasal obstruction is mediated via a variety of
mechanisms, including dilatation of the nasal vascula-
ture, mucosal edema, the presence of polyps, and
physical deformities, which reduce nasal cavity diam-
eter and thus impede airflow.11 Superimposed on this
is a degree of sensory modulation that contributes to
nasal congestion symptoms, with or without the phys-
ical obstruction. A major component of nasal obstruc-
tion is the engorgement of the nasal vasculature, which
is richly innervated by fibers of the ANS.10,15 Sympa-
thetic tone, by causing vasoconstriction and emptying
of the venous sinusoids via control of arteriovenous
anastomoses, is the most important determinant in
nasal patency. A reduction in sympathetic tone causes
venous sinusoids dilatation and contributes to symp-
toms of nasal obstruction (Fig. 1).
This sympathetic tone is predominantly mediated by
the effect of noradrenaline on the -1 receptors in the
venous sinusoids, which act as the capacitance vessels,
whereas -2 receptors have a greater role in the control
of arteriole constriction and act as the “resistance”
blood vessels.16 In contrast, -adrenoreceptor stimula-
tion results in vasodilatation and increased blood flow,
although the effect of alpha stimulation is more pro-
nounced.17 Chemical and surgical attenuation of sym-
pathetic innervation to the nose in both cat models and
humans results in nasal obstruction.18–21 For example,
topically applied -adrenergic antagonists, e.g., phe-
noxybenzamine, inhibit -adrenergic–mediated nasal
vasoconstriction in cat mucosa. Conversely, stimula-
tion of sympathetic activity in the cervical chain in
dogs decreases nasal airway resistance and decreases
vessel capacitance.22 Humans exposed to upright pos-
ture change, exercise, or temperature changes devel-
oped increased sympathetic tone, measured with HRV,
and improved nasal flow.23–25 The response to exercise
can be inhibited by injection of anesthetic into the
superior cervical ganglion.
Parasympathetic nerve stimulation in the nose has
the opposite effect on the venous capacitance vessels
and causes their dilatation via the action of acetylcho-
line on M1 and M3 muscarinic receptors as well as
releases vasoactive intestinal peptide and nitric oxide,
the final mediator of endothelium-derived relaxation
factor.15,17,26 A small study of 26 patients with vaso-
motor rhinitis demonstrated HRV, indicated hyper-
active parasympathetic activity compared with con-
trols without rhinitis.27 Prevention of acetylcholine
secretion with botulinum toxin reduces the symp-
toms of nasal obstruction characteristic of rhinitis.28
Both sympathetic and parasympathetic components
are suggested to play a role in alternating unilateral
nasal obstruction symptoms that behave much like an
exaggerated nasal cycle.17 It has been demonstrated
that attenuation of either sympathetic or parasympa-
thetic innervation to the nose obliterates the nasal cycle
phenomenon.
Nasal Discharge
Nasal discharge is the net result of a combination of
plasma extravasation from the dilated vessels, inflam-
mation, cell debris, and secretion from submucosal
nasal glands and goblet cells.29 Glandular secretion is
controlled by the balance of parasympathetic and sym-
pathetic activity in the nose.30 Stimulation of parasym-
pathetic activity results in increased nasal secretions
rich in lysozyme, immunoglobulin A and glycopro-
teins.29 Electrical stimulation of the feline vidian nerve
increases the rate and flow of nasal secretion in a
dose-dependent manner.18 This effect also occurs when
a particular area of the brainstem is stimulated, accom-
panied by an increase in systemic blood pressure,
likely due to simultaneous stimulation of the sympa-
thetic nervous system, which implicates an important
role for the brainstem in ANS activity in the nose.
In addition, chemical stimulation with the muscarinic
agonist methacholine applied topically was shown to
significantly increase nasal secretions in humans.31 Pa-
tients with chronic rhinorrhea secondary to idiopathic
perennial rhinitis demonstrate hypervagal tone on objec-
tive autonomic evaluation.32 The secretory response is
attenuated by chemical or surgical inhibition of cholin-
ergic and vagal stimulation. A Cochrane systematic re-
view, which included seven trials, highlights that iprat-
2
ropium bromide in patients with common cold have a
reduction in rhinorrhea.33 Chemical neuromuscular dis-
ruption of acetylcholine release with botulinum toxin can
also be used to effectively treat refractory rhinitis.28 A
recent systematic review, which included eight trials,
concluded that endoscopic vidian neurectomy is effective
at reducing rhinorrhea in patients with intractable non-
allergic rhinitis.34 These interventions act via a common
pathway that involves the acetylcholine-stimulated G-
protein-coupled M3 muscarinic receptor, which stimu-
lates cyclic guanosine monophosphate and promotes se-
cretion of glandular cells.
Rhinorrhea symptoms similarly represent an imbal-
ance between parasympathetic and sympathetic activ-
ity, with a predominance toward parasympathetic hy-
peractivity. Pupillometric measurement as a measure
of autonomic activity indicates a relative parasympa-
thetic hyperactivity with sympathetic hypoactivity in
children with allergic rhinitis compared with those
without allergic rhinitis.35 Similarly, inhibition of sym-
pathetic activity with systemic -antagonists and in-
verse agonists (e.g., tamsulosin and doxazosin) used for
non-nasal conditions have been associated with ad-
verse effects of rhinitis and nasal obstruction.36,37
Neuropeptides from autonomic nerves can incite
and modulate the inflammatory response and vaso-
dilatation as part of the neurogenic inflammation
process. The Cochrane Library defines neurogenic
inflammation as the “injurious stimulus of periph-
eral neurons and resulting release of neuropeptides
which affect vascular permeability and help initiate
proinflammatory and immune reactions at the site of
injury.”38 Nasal mucosal inflammation potentially
contributes to a variety of symptoms, from obstruc-
tion to hyposmia.39 The neuromodulatory role of the
ANS has been indicated to be an important compo-
nent in the response toward potential noxious envi-
ronmental stimuli.40
Denervation of autonomic nerves in a rat model
suppresses nasal secretion and decreases levels of neu-
ropeptides, including substance P, calcitonin gene-re-
lated peptide, vasoactive intestinal peptide, and neu-
ropeptide Y (NP).41 A role for these neuropeptides also
extends to humans. NPY is a neuropeptide released
from adrenergic nerve endings, co-localized with nor-
epinephrine, and acts as a neuromodulator. NPY is
regulated, in part, by the inhibitory autoreceptor NPY2
located on presynaptic neurons.42 Increased levels of
NPY are associated with vasoconstriction, increased
nasal patency, and decreased levels of nitric ox-
ide.43,44
Substance P also seems to be an important mediator
of neurogenic inflammation in conditions such as non-
allergic rhinitis.45,46 Substance P receptors (neurokinin
1 receptor) are expressed in afferent nerves in submu-
cosal glands and airway mucosa.47 A randomized con-
Figure 1. Summary of the pathophysiology of sinonasal symptoms in symptomatic and non-symptomatic individuals. CGRP  calcitonin
gene-related peptide; NA  noradrenaline; NPY  neuropeptide Y; TRPV1  transient receptor potential cation channel subfamily V
member 1; VIP  vasoactive intestinal peptide.
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trolled trial that used the substance P-depleting effects
of capsaicin demonstrated symptom improvements in
patients within non-allergic rhinitis when applied top-
ically for 2 weeks.48 Similarly, the topical application of
histamine antagonist azelastine is associated with re-
duced substance P levels and improved vasomotor
rhinitis symptom scores.49 Recent evidence indicates a
role of neuropeptides, such as substance P and brady-
kinin, in immunomodulation. The neuropeptide calci-
tonin-related gene peptide is a known potent vasodi-
lator50 whose receptors are found in the nose and
paranasal sinuses.51 Its importance in the autonomic
regulation of the vasculature is becoming increasingly
recognized.52
Histamine released from degranulating nasal mast
cells triggers acute allergic rhinitis symptoms,53 which
can be inhibited by topical antihistamines.54 More re-
cent evidence indicates that histamine may also have a
role as a neuromodulator of the ANS.55 Histamine
seems to inhibit the release of norepinephrine from
sympathetic nerve endings that innervate the nasal
vasculature. Immunohistochemical staining and real-
time polymerase chain reaction work carried out on
inferior turbinate tissue indicates that histamine acts
in this role via H3 histamine receptors, which causes
overall vasodilatation.55 The relationship between
inflammation and ANS activity is potentially bidi-
rectional because chronic inflammation can upregu-
late neural hyperresponsiveness and potentiate neu-
rogenic inflammation.17
Sneezing and Reflexes
The importance of the ANS in the immunomodula-
tory role has long been known.56 Similarly, the ANS
has an important protective role in airway reflexes that
reacts to potentially harmful stimuli. For example, a
sneeze-provoking intranasal stimulus mediates the af-
ferent reflex limb via H1 receptors and the trigeminal
nerve.57 The efferent response is coordinated by the
brainstem via multiple central nuclei and pathways. In
the first phase of sneezing (nasal-sensitive phase),
parasympathetic fibers travel via the superficial petro-
sal nerve and the sphenopalatine ganglion, and cause
nasal mucosal secretion. Such responses are bilateral
and initiated by parasympathetic fibers that derive
from the superior salivary nucleus.57 The resultant
edema causes trigeminal stimulation and a positive
feedback loop, summating neural impulses into the
putative sneezing center in the medulla.58
When a threshold is reached, the second phase (re-
spiratory phase) is initiated, which results in a systemic
stereotyped and coordinated muscular response that
involves abdominal, thoracic, pharyngeal, and facial
muscles. Anticholinergic agents are able to inhibit the
first phase of sneezing. A randomized controlled trial
of 411 participants with cold symptoms demonstrated
a suppression of the sneeze reflex by intranasal appli-
cation of the anticholinergic agent ipratropium.59 Fur-
ther evidence from patients with allergic rhinitis sup-
ports the role of the ANS in sneezing. In a small study,
10 patients with allergic rhinitis were stimulated with
an intranasal allergen, and responses in airflow resis-
tance and HRV were recorded.60 After stimulation,
nasal airflow resistance increased, accompanied by de-
creasing LF and the LF:HF ratio, which indicates sym-
pathetic activity withdrawal compared with relatively
stable parasympathetic tone.60 These findings indi-
cated that sneezing, in addition to rhinorrhea and ob-
struction, respond to changes in the balance of sympa-
thetic and parasympathetic activity.
The ANS may represent a final common pathway for
other nasal reflexes that occur in response to varied
provoking stimuli, such as cold, capsaicin, and toxic
inhalants.57 The attenuation of nasal secretion and va-
sodilatation responses to stimuli, such as histamine
and cold with vidian neurectomy or anticholinergic
agents, indicate that these are neurally mediated re-
flexes.8,61,62 Patients with allergic rhinitis demonstrate
a heightened symptomatic response to such stimuli
compared with healthy subjects without allergy. It is
postulated that this phenomenon is caused by lowered
sensory nerve thresholds or antidromic stimulation
from neuropeptides that are driving neural hyperre-
sponsiveness.17 Inhibition of the nasal sensory fibers in
the afferent limb of these reflexes with small doses of
capsaicin causes desensitization and is associated with
decreased levels of the transient receptor potential cat-
ion channel subfamily V member 1 (TRPV1) and de-
creased rhinitis symptoms.48,63
Polyps
There is little evidence for the role of the ANS in
polyp disease, although, on histologic examination, the
nasal polyp pedicle is richly innervated by sympathetic
nerves.64
Facial Pain
The ANS has an important role in cholinergic symp-
toms associated with facial pain syndromes. Facial
pain syndromes, e.g., mid segment facial pain, may
pose difficult diagnostic and treatment challenges to
the otolaryngologist.65 The rhinorrhea seen with tri-
geminal autonomic cephalgias and migraine are attrib-
utable to parasympathetic activation. Blockade of this
trigeminal-autonomic reflex via surgery or local anes-
thetic has traditionally been used to successfully treat
refractory rhinorrhea and facial pain.66 A small ran-
domized controlled trial of 20 patients who underwent
sphenopalatine ganglion acupuncture demonstrated
significant subjective and objective airway patency im-
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provements compared with sham controls.43 More re-
cently, the successful use of oxygen therapy to treat the
symptoms of cluster headache has been indicated to be
attributable to the effect of oxygen as an anti-inflam-
matory neuromodulator.67,68
WHAT ROLE MIGHT THE ANS HAVE IN
CONNECTING SINONASAL DISEASE TO
SYSTEMIC DISEASES?
Rhinitis and Blood Pressure
The diving reflex phenomenon suggests a neurally
mediated connection between nasal stimuli and cardio-
respiratory control.69 The relationship between rhinitis
and blood pressure remains controversial. European-
based population studies of 330 men with rhinitis con-
cluded that rhinitis is associated with increased blood
pressure in men.70,71 However, more recently, a U.S.-
based population study of 3912 men and women found
no such association.72 Interestingly, treatment of aller-
gic rhinitis in patients reduces their systolic blood pres-
sure.73 The shared importance of the ANS in nasal
symptoms and blood pressure control certainly impli-
cates the possibility that autonomic dysfunction may
link both of these conditions, although evidence for
causality is currently limited.
Sinonasal Symptoms and Lower Airways Disease
Sinonasal diseases such as allergic rhinitis and rhi-
nosinusitis have been associated with several lower
airway conditions, including asthma and bronchiecta-
sis through the unified airway hypothesis.74–76 Cold
nasal stimulus and apnea are linked via the diving
reflex.69 However, the role of the ANS in this relation-
ship is not entirely clear. Several physiologic studies
over the past 3 decades demonstrate a connection be-
tween upper airways inflammation, e.g., in sinusitis or
nasal cold stimulus, with lower airway bronchocon-
striction through the mechanism of inflammatory seed-
ing or reflex.77–79 This response is attenuated by local
anesthesia or anticholinergic agents topically applied
to the nose.
Our more recent understanding of the unified airway
implicates the important role of the ANS in host de-
fense and neuroimmunomodulatory function, e.g., in
allergy.80 The impact of allergy on neuronal activity is
complex and acts on multiple levels, e.g., by increasing
sensory nerve excitability, central sensitization, and
synaptic efficiency, and by changes to nerve end trans-
mitter release. Potentially harmful stimuli causing C
fiber activation in the upper airway (e.g., from nasal or
laryngeal mucosa) have been postulated to cause cen-
tral sensitization of stimuli from the lower airways,
which results in increased lower airway reflex re-
sponses (such as cough and bronchospasm).81,82 The
precise mechanisms by which these occur in man re-
main unclear.
Sinonasal Symptoms and Gastroesophageal Reflux
Patients with chronic rhinosinusitis (CRS) are more
likely to have gastroesophageal reflux disease (GERD)
compared with those without CRS.83 GERD is also
associated with increased symptom burden in patients
with CRS.84 Moreover, in a cohort of 182 patients who
were undergoing functional endoscopic sinus surgery,
gastroesophageal reflux was the only condition signif-
icantly associated with a poor symptomatic outcome
after surgery.85 However, there is evidence that an
involvement of autonomic dysfunction that links
GERD and sinusitis is limited to small studies. In a
study of 15 patients, excessive vagal responses were
found in those with concomitant asthma and GERD.86
Loehrl et al.87 describe patients with vasomotor rhinitis
with or without GERD to have relative adrenergic
hypoactivity compared with healthy controls. There
was more significant adrenergic hypoactivity in the
vasomotor rhinitis group with GERD compared with
those without GERD. Although autonomic dysfunc-
tion is a feature of GERD and sinonasal disease, there
is little explanation offered for the pathophysiology of
ANS dysfunction in this association.
Sinonasal Symptoms and Drug Adverse Effects
Drugs that act on the ANS can have a vasoactive
effect on the nose, which causes nasal obstruction and
rhinorrhea.88 For example, nasal obstruction is a rec-
ognized adverse effect of -blockers, e.g., tamsulosin
(commonly used in benign prostatic hypertrophy
management) and doxazosin (used in hypertension
treatment). Other medications causing nasal obstruc-
tion adverse effects and include certain psychotropic
drugs (e.g., chlorpromazine), peripheral vasodilators
(e.g., sildenafil), and hormonal treatments (e.g., es-
trogen).88
WHAT ARE THE FACTORS AND MECHANISMS
THAT DRIVE ANS DYSFUNCTION IN
SINONASAL DISEASE?
Allergy
Host response to external allergen has been postu-
lated to affect autonomic function.89 In the sinonasal
inflammatory environment, Kubo and Kumazawa90
describe a stimulated parasympathetic state, with up-
regulated muscarinic receptors, and simultaneous ad-
renergic hypofunction characterized by downregula-
tion of - and -adrenoreceptors.90 This phenotype is
supported by objective airflow measurement and
HRV analysis, which measures ANS function.60 Our
more recent understanding of molecular neurobiol-
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ogy places an emphasis on the immunomodulatory
role of the ANS.
Stimulation with allergenic mediators can also cause
long-term changes by increasing neuronal excitability,
increasing synaptic efficiency, and modifying gene ex-
pression and neuron phenotype.81 These changes are
consistent with mucosal hypersensitivity described in
patients with allergic rhinitis. Noradrenaline released
from sympathetic nerve endings act on - and -ad-
renergic receptors present on macrophages, T cells, B
cells, and natural killer (NK) cells.91 In the parasympa-
thetic nervous system, vagus afferents are thought to
play a role in antigen detection. Parasympathetic efferent
activity mediates cholinergic anti-inflammatory proper-
ties, which thus completes the “inflammatory reflex.”92
Macrophages, for example, express the nicotinic acetyl-
choline receptor and are highly sensitive to modulation
by the cholinergic pathway.
Stress
Physical or psychogenic stressors may represent an
important etiologic factor for ANS dysfunction. Stress
and anxiety are associated with allergic rhinitis and
CRS.93–95 Eccles96 noted that psychological stress can
cause instability of hypothalamic function and disrupt
the autonomic balance in the nasal cycle, migraine, and
Meniere’s disease. Psychological stressors, e.g., mental
arithmetic or an interview about an upsetting asthma-
related incident, were shown to increase parasympa-
thetic activity, which is associated with poor asthma
control.97 Inhibition of cholinergic function with the
anticholinergic agent ipratropium bromide attenuates
the increase in airflow resistance after emotionally
stressful stimuli.98 It has also been suggested that stress
in utero may program maladaptive neuroimmuno-
modulatory ANS responses via epigenetic effects, pre-
disposing to allergy from an early age.99,100
Physical stressors, such as changes in air tempera-
ture, humidity, dust, and noxious chemicals, can in-
duce autonomic-mediated symptoms, such as obstruc-
tion and rhinorrhea, in the short term.101 However,
episodic exposure to temperature extremes may also
affect autonomic function over longer periods. A small
study, of 26 patients with allergic rhinitis, found that a
6-week course of high-temperature sauna treatment
increased sympathetic activity as measured by HRV
and increased peak nasal flow.23 Overall, it is possible
to hypothesize a complex relationship in which psy-
chological stressors and physical stressors drive mech-
anisms of ANS dysfunction. The resulting pathophys-
iologic changes as well as personal psychological
factors can influence the reporting of sinonasal symp-
toms (Fig. 2).
CONCLUSION
The significance of the clinical burden of the ANS on
otorhinolaryngologic disorders was highlighted by
Hilger102 over 60 years ago. However, our understand-
ing of the pathophysiology of ANS dysfunction is lim-
ited by mostly level 5 evidence in small studies with a
lack of recent updates. Important potential clinical im-
plications urge further research. Characterizing molec-
ular mechanisms in nasal ANS offers potential new
targets for intervention within neurogenic inflamma-
tion in CRS.103 For example, the neuroimmunomodu-
latory effects of botulinum toxin A showed promise in
alleviating symptoms of refractory rhinitis and aller-
gic rhinitis.28,104 TRPV receptor antagonists have
also emerged as a novel anti-inflammatory class.105,106
In addition, a better understanding of the etiology of
ANS dysfunction, especially in relation to stress, po-
tentially opens new treatment pathways for patients,
e.g., psychological therapy, which includes cognitive
behavioral therapy and mindfulness.
The mechanisms from which sinonasal symptoms
arise are complex and involve psychological, physical,
and biochemical factors. ANS dysfunction is likely to
represent just one contributor among many factors that
drive sinonasal symptoms. More research is required
to (1) establish the direction of causality between ANS
Figure 2. Illustration of the complex relationship between psychological factors, physical factors and sinonasal symptoms.
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dysfunction and sinonasal disease, and (2) determine
the etiologic factors that drive ANS dysfunction in the
first place.
ETHICAL APPROVAL
This study was approved by our institutional review
board.
STATEMENT OF HUMAN AND ANIMAL
RIGHTS
This article does not contain any studies with human
or animal subjects.
STATEMENT OF INFORMED CONSENT
There are no human subjects in this article and in-
formed consent is not applicable.
REFERENCES
1. Lewis MJ, Short AL, Lewis KE. Autonomic nervous system
control of the cardiovascular and respiratory systems in
asthma. Respir Med. 2006; 100:1688–1705.
2. van Gestel AJ, Steier J. Autonomic dysfunction in patients with
chronic obstructive pulmonary disease (COPD). J Thorac Dis.
2010; 2:215–222.
3. Stachler RJ. Comorbidities of asthma and the unified airway.
Int Forum Allergy Rhinol. 2015; 5(suppl. 1):S17–S22.
4. Frieri M, Kumar K, Boutin A. Review: Immunology of sinus-
itis, trauma, asthma, and sepsis. Allergy Rhinol (Providence).
2015; 6:205–214.
5. Frieri M. Asthma linked with rhinosinusitis: An extensive
review. Allergy Rhinol (Providence). 2014; 5:41–49.
6. Dawes JD, Prichard MM. Studies of the vascular arrangements
of the nose. J Anat. 1953; 87:311–322.
7. Millonig AF, Harris HE, Gardner WJ. Effect of autonomic
denervation on nasal mucosa; interruption of sympathetic and
parasympathetic fibers. Arch Otolaryngol. 1950; 52:359–372.
8. Konno A, Togawa K. Role of the vidian nerve in nasal allergy.
Ann Otol Rhinol Laryngol. 1979; 88(pt. 1):258–266.
9. Assis E, Isido´rio U, Feitosa A, et al. Autonomic Nervous Sys-
tem and Allergic Diseases: Integrative Literature Review. In-
ternational Archives of Medicine. 2015; 8(112):1–6.
10. Sahin-Yilmaz A, Naclerio RM. Anatomy and physiology of the
upper airway. Proc Am Thorac Soc. 2011; 8:31–39.
11. Naclerio RM, Bachert C, Baraniuk JN. Pathophysiology of
nasal congestion. Int J Gen Med. 2010; 3:47–57.
12. Zygmunt A, Stanczyk J. Methods of evaluation of autonomic
nervous system function. Arch Med Sci. 2010; 6:11–18.
13. Berntson GG, Bigger JT Jr, Eckberg DL, et al. Heart rate vari-
ability: Origins, methods, and interpretive caveats. Psycho-
physiology. 1997; 34:623–648.
14. Billman GE. The LF/HF ratio does not accurately measure
cardiac sympatho-vagal balance. Front Physiol. 2013; 4:26.
15. Baraniuk JN, Merck SJ. Neuroregulation of human nasal mu-
cosa. Ann N Y Acad Sci. 2009; 1170:604–609.
16. Corboz MR, Rivelli MA, Varty L, et al. Pharmacological char-
acterization of postjunctional alpha-adrenoceptors in human
nasal mucosa. Am J Rhinol. 2005; 19:495–502.
17. Sarin S, Undem B, Sanico A, Togias A. The role of the nervous
system in rhinitis. J Allergy Clin Immunol. 2006; 118:999–1016.
18. Eccles R, Wilson H. The parasympathetic secretory nerves of
the nose of the cat. J Physiol. 1973; 230:213–223.
19. Lundblad L, Anggard A, Saria A, Lundberg JM. Neuropeptide
Y and non-adrenergic sympathetic vascular control of the cat
nasal mucosa. J Auton Nerv Syst. 1987; 20:189–197.
20. Moore D. Stellate Ganglion Block. Springfield, IL: Charles C.
Thomas, 1954.
21. Riechelmann H, and Krause W. Autonomic regulation of nasal
vessels during changes in body position. Eur Arch Otorhino-
laryngol. 1994; 251:210–213.
22. Lung MA, Wang JC. Autonomic nervous control of nasal
vasculature and airflow resistance in the anaesthetized dog.
J Physiol. 1989; 419:121–139.
23. Kunbootsri N, Janyacharoen T, Arrayawichanon P, et al. The
effect of six-weeks of sauna on treatment autonomic nervous
system, peak nasal inspiratory flow and lung functions of
allergic rhinitis Thai patients. Asian Pac J Allergy Immunol.
2013; 31:142–147.
24. Ko JH, Kuo TB, Lee GS. Effect of postural change on nasal
airway and autonomic nervous system established by rhino-
manometry and heart rate variability analysis. Am J Rhinol.
2008; 22:159–165.
25. Richerson HB, and Seebohm PM. Nasal airway response to
exercise. J Allergy. 1968; 41:269–284.
26. Maniscalco M, Bianco A, Mazzarella G, Motta A. Recent ad-
vances on nitric oxide in the upper airways. Curr Med Chem.
2016; 23:2736–2745.
27. Vayisoglu Y, Ozcan C, Pekdemir H, et al. Autonomic nervous
system evaluation using heart rate variability parameters in
vasomotor rhinitis patients. J Otolaryngol. 2006; 35:338–342.
28. Ozcan C, and Ismi O. Botulinum toxin for rhinitis. Curr Al-
lergy Asthma Rep. 2016; 16:58.
29. Kaliner MA. The physiology and pathophysiology of the para-
sympathetic nervous system in nasal disease: An overview. J
Allergy Clin Immunol. 1992; 90(pt. 2):1044–1045.
30. Tai CF, and Baraniuk JN. Upper airway neurogenic mecha-
nisms. Curr Opin Allergy Clin Immunol. 2002; 2:11–19.
31. Borum P. Nasal methacholine challenge. A test for the mea-
surement of nasal reactivity. J Allergy Clin Immunol. 1979;
63:253–257.
32. Elsheikh MN, Badran HM. Dysautonomia rhinitis: Associated
otolaryngologic manifestations and characterization based on
autonomic function tests. Acta Otolaryngol. 2006; 126:1206–
1212.
33. AlBalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium
bromide for the common cold. Cochrane Database Syst Rev.
2013; (6):CD008231.
34. Marshak T, Yun WK, Hazout C, et al. A systematic review of
the evidence base for vidian neurectomy in managing rhinitis.
J Laryngol Otol. 2016; 130(suppl. 4):S7–S28.
35. Ozsutcu M, Ozkaya E, Demir A, et al. Pupillometric assess-
ment of autonomic nervous system in children with allergic
rhinitis. Med Princ Pract. 2013; 22:444–448.
36. British National Formulary, 72nd ed. London: BMJ Group and
Pharmaceutical Press, 2016.
37. Manoharan A, Morrison AE, Lipworth BJ. Effects of the in-
verse alpha-agonist doxazosin in allergic rhinitis. Clin Exp
Allergy. 2016; 46:696–704.
38. Cochrane Library. Definition. Neurogenic Inflammation. 2017.
Available online at http://onlinelibrary.wiley.com/cochraneli-
brary/search/mesh?searchRow.searchOptions.conceptId
D020078&searchRow.searchCriteria.meshTermNeurogenic%
20Inflammation&meshConceptUpdate&searchRow.ordinal
0&hiddenFields.strategySortBylast-modified-date;desc&
hiddenFields.showStrategiesfalse; accessed October 1, 2017.
39. Gaines AD. Anosmia and hyposmia. Allergy Asthma Proc.
2010; 31:185–189.
40. Tizzano M, Finger TE. Chemosensors in the nose: Guardians of
the airways. Physiology (Bethesda). 2013; 28:51–60.
Allergy & Rhinology 7
41. Nishijima H, Kondo K, Toma-Hirano M, et al. Denervation of
nasal mucosa induced by posterior nasal neurectomy sup-
presses nasal secretion, not hypersensitivity, in an allergic
rhinitis rat model. Lab Invest. 2016; 96:981–993.
42. Chen X, DiMaggio DA, Han SP, Westfall TC. Autoreceptor-
induced inhibition of neuropeptide Y release from PC-12 cells
is mediated by Y2 receptors. Am J Physiol. 1997; 273(pt. 2):
H1737–H1744.
43. Wang K, Chen L, Wang Y, et al. Sphenopalatine ganglion
acupuncture improves nasal ventilation and modulates auto-
nomic nervous activity in healthy volunteers: A randomized
controlled study. Sci Rep. 2016; 6:29947.
44. Cervin A, Onnerfalt J, Edvinsson L, Grundemar L. Functional
effects of neuropeptide Y receptors on blood flow and nitric
oxide levels in the human nose. Am J Respir Crit Care Med.
1999; 160(pt. 1):1724–1728.
45. Bernstein JA, Singh U. Neural abnormalities in nonallergic
rhinitis. Curr Allergy Asthma Rep. 2015; 15:18.
46. Widdicombe JG. Nasal pathophysiology. Respir Med. 1990;
84(suppl. A):3–9; discussion 9–10.
47. Shirasaki H, Asakura K, Narita SI, Kataura A. Expression of
substance P (NK1) receptor mRNA in human nose. Acta Oto-
laryngol. 1998; 118:717–722.
48. Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-
blind, parallel trial comparing capsaicin nasal spray with pla-
cebo in subjects with a significant component of nonallergic
rhinitis. Ann Allergy Asthma Immunol. 2011; 107:171–178.
49. Gawlik R, Jawor B, Rogala B, et al. Effect of intranasal azelas-
tine on substance P release in perennial nonallergic rhinitis
patients. Am J Rhinol Allergy. 2013; 27:514–516.
50. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-
related peptide is a potent vasodilator. Nature. 1985; 313:
54–56.
51. Sato I, Imura K, Miwa Y, et al. Distributions of calcitonin
gene-related peptide and substance P in the human maxillary
sinus of Japanese cadavers. J Craniomaxillofac Surg. 2012;
40:e249–e252.
52. Mai TH, Wu J, Diedrich A, et al. Calcitonin gene-related pep-
tide (CGRP) in autonomic cardiovascular regulation and vas-
cular structure. J Am Soc Hypertens. 2014; 8:286–296.
53. Frieri M, Kumar K, Boutin A. Role of mast cells in trauma and
neuroinflammation in allergy immunology. Ann Allergy
Asthma Immunol. 2015; 115:172–177.
54. Mygind N, Secher C, and Kirkegaard J. Role of histamine and
antihistamines in the nose. Eur J Respir Dis Suppl. 1983;
128(pt. 1):16–20.
55. Suzuki S, Takeuchi K, and Majima Y. Localization and func-
tion of histamine H3 receptor in the nasal mucosa. Clin Exp
Allergy. 2008; 38:1476–1482.
56. Nance DM, Sanders VM. Autonomic innervation and regula-
tion of the immune system (1987–2007). Brain Behav Immun.
2007; 21:736–745.
57. Baraniuk JN, Kim D. Nasonasal reflexes, the nasal cycle, and
sneeze. Curr Allergy Asthma Rep. 2007; 7:105–111.
58. Seijo-Martínez M, Varela-Freijanes A, Grandes J, and Va´zquez
F. Sneeze related area in the medulla: Localisation of the
human sneezing centre? J Neurol Neurosurg Psychiatry. 2006;
77:559–561.
59. Hayden FG, Diamond L, Wood PB, et al. Effectiveness and
safety of intranasal ipratropium bromide in common colds. A
randomized, double-blind, placebo-controlled trial. Ann In-
tern Med. 1996; 125:89–97.
60. Seppanen TM, Alho OP, Seppanen T. Concomitant dynamic
changes in autonomic nervous system function and nasal air-
flow resistance during allergen provocation. Conf Proc IEEE
Eng Med Biol Soc. 2015; 2015:3339–3342.
61. Konno A, Togawa K, Fujiwara T. The mechanisms involved in
onset of allergic manifestations in the nose. Eur J Respir Dis
Suppl. 1983; 128(pt. 1):155–166.
62. Cruz AA, Togias A. Upper airways reactions to cold air. Curr
Allergy Asthma Rep. 2008; 8:111–117.
63. Van Gerven L, Alpizar YA, Wouters MM, et al. Capsaicin
treatment reduces nasal hyperreactivity and transient receptor
potential cation channel subfamily V, receptor 1 (TRPV1) over-
expression in patients with idiopathic rhinitis. J Allergy Clin
Immunol. 2014; 133:1332–1339.e1–e3.
64. Lin JK, Wang HW, Su WY. Noradrenergic innervation of nasal
polyps and polypoid mucosae. Auris Nasus Larynx. 1996;
23:121–126.
65. Jones NS. Midfacial segment pain: Implications for rhinitis and
sinusitis. Curr Allergy Asthma Rep. 2004; 4:187–192.
66. Robbins MS, Robertson CE, Kaplan E, et al. The sphenopala-
tine ganglion: Anatomy, pathophysiology, and therapeutic tar-
geting in headache. Headache. 2016; 56:240–258.
67. Petersen AS, Barloese MC, Jensen RH. Oxygen treatment of
cluster headache: A review. Cephalalgia. 2014; 34:1079–1087.
68. Akerman S, Holland PR, Lasalandra MP, and Goadsby PJ.
Oxygen inhibits neuronal activation in the trigeminocervical
complex after stimulation of trigeminal autonomic reflex, but
not during direct dural activation of trigeminal afferents.
Headache. 2009; 49:1131–1143.
69. Panneton WM. The mammalian diving response: An enig-
matic reflex to preserve life? Physiology. 2013; 28:284–297.
70. Kony S, Zureik M, Neukirch C, et al. Rhinitis is associated with
increased systolic blood pressure in men: A population-based
study. Am J Respir Crit Care Med. 2003; 167:538–543.
71. Heinrich J, Doring A. Blood pressure and rhinitis in adults:
Results of the MONICA/KORA-study. J Hypertens. 2004; 22:
889–892.
72. Li C, Cheung CL, Cheung TT, et al. Hay fever and hypertension
in the US adult population. Clin Exp Hypertens. 2014; 36:206–
210.
73. Magen E, Yosefy C, Viskoper RJ, Mishal J. Treatment of aller-
gic rhinitis can improve blood pressure control. J Hum Hyper-
tens. 2006; 20:888–893.
74. Guilemany JM, Angrill J, Alobid I, et al. United airways again:
high prevalence of rhinosinusitis and nasal polyps in bronchi-
ectasis. Allergy. 2009; 64:790–797.
75. Ryan MW, Clark CM. Allergic fungal rhinosinusitis and the
unified airway: The role of antifungal therapy in AFRS. Curr
Allergy Asthma Rep. 2015; 15:75.
76. Ramakrishnan JB, Kingdom TT, Ramakrishnan VR. Allergic
rhinitis and chronic rhinosinusitis: Their impact on lower air-
ways. Immunol Allergy Clin North Am. 2013; 33:45–60.
77. Bucca C, Rolla G, Scappaticci E, et al. Extrathoracic and in-
trathoracic airway responsiveness in sinusitis. J Allergy Clin
Immunol. 1995; 95(pt. 1):52–59.
78. Irvin CG. Sinusitis and asthma: An animal model. J Allergy
Clin Immunol. 1992; 90(pt. 2):521–533.
79. Fontanari P, Burnet H, Zattara-Hartmann MC, and Jammes Y.
Changes in airway resistance induced by nasal inhalation of
cold dry, dry, or moist air in normal individuals. J Appl
Physiol (1985). 1996; 81:1739–1743.
80. Wells R, Tonkin A. Clinical approach to autonomic dysfunc-
tion. Intern Med J. 1996; 46:1134–1139.
81. Undem BJ, Taylor-Clark T. Mechanisms underlying the neu-
ronal-based symptoms of allergy. J Allergy Clin Immunol.
2014; 133:1521–1534.
82. Tatar M, Plevkova J, Brozmanova M, et al. Mechanisms of the
cough associated with rhinosinusitis. Pulm Pharmacol Ther.
2009; 22:121–126.
83. Mahdavinia M, Bishehsari F, Hayat W, et al. Prevalence of
allergic rhinitis and asthma in patients with chronic rhinosi-
8
nusitis and gastroesophageal reflux disease. Ann Allergy
Asthma Immunol. 2016; 117:158–162.e1.
84. Bohnhorst I, Jawad S, Lange B, et al. Prevalence of chronic
rhinosinusitis in a population of patients with gastroesopha-
geal reflux disease. Am J Rhinol Allergy. 2015; 29:e70–e74.
85. Chambers DW, Davis WE, Cook PR, et al. Long-term outcome
analysis of functional endoscopic sinus surgery: Correlation of
symptoms with endoscopic examination findings and poten-
tial prognostic variables. Laryngoscope. 1997; 107:504–510.
86. Lodi U, Harding SM, CoghlanHC, et al. Autonomic regulation in
asthmatics with gastroesophageal reflux. Chest. 1997; 111:65–70.
87. Loehrl TA, Smith TL, Darling RJ, et al. Autonomic dysfunc-
tion, vasomotor rhinitis, and extraesophageal manifestations
of gastroesophageal reflux. Otolaryngol Head Neck Surg.
2002; 126:382–387.
88. Cingi C, Ozdoganoglu T, Songu M. Nasal obstruction as a
drug side effect. Ther Adv Respir Dis. 2011; 5:175–182.
89. Williams HL. A concept of allergy as autonomic dysfunction
suggested as an improved working hypothesis. Trans Am
Acad Ophthalmol Otolaryngol. 1950; 55:123–146.
90. Kubo N, Kumazawa T. Functional disturbances of the auto-
nomic nerve in nasal hyperreactivity: An up-date review. Acta
Otolaryngol Suppl. 1993; 500:97–108.
91. Kenney MJ, Ganta CK. Autonomic nervous system and immune
system interactions. Compr Physiol. 2014; 4:1177–1200.
92. Tracey KJ. Reflex control of immunity. Nat Rev Immunol.
2009; 9:418–428.
93. Vamanshankar H, Hegde KS, Chaturvedi J, et al. Do patients
with allergic rhinitis have a particular personality trait? J
Laryngol Otol. 2013; 127:378–382.
94. Seok H, Yoon JH, Won JU, et al. Concealing emotions at work
is associated with allergic rhinitis in Korea. Tohoku J Exp Med.
2016; 238:25–32.
95. Tomljenovic D, Pinter D, Kalogjera L. Perceived stress and
severity of chronic rhinosinusitis in allergic and nonallergic
patients. Allergy Asthma Proc. 2014; 35:398–403.
96. Eccles R, Eccles KS. Asymmetry in the autonomic nervous
system with reference to the nasal cycle, migraine, anisocoria
and Meniere’s syndrome. Rhinology. 1981; 19:121–125.
97. Aboussafy D, Campbell TS, Lavoie K, et al. Airflow and auto-
nomic responses to stress and relaxation in asthma: The impact
of stressor type. Int J Psychophysiol. 2005; 57:195–201.
98. Ritz T, Simon E, and Trueba AF. Stress-induced respiratory
pattern changes in asthma. Psychosom Med. 2011; 73:514–521.
99. Wright RJ. Stress-related programming of autonomic imbal-
ance: Role in allergy and asthma. Chem Immunol Allergy.
2012; 98:32–47.
100. Harris A, Seckl J. Glucocorticoids, prenatal stress and the
programming of disease. Horm Behav. 2011; 59:279–289.
101. Shusterman D. Nonallergic rhinitis: Environmental determi-
nants. Immunol Allergy Clin North Am. 2016; 36:379–399.
102. Hilger JA. Autonomic dysfunction in otolaryngology. Trans
Am Acad Ophthalmol Otolaryngol. 1951; 55:716–723.
103. Frieri M. Neuroimmunology and inflammation: Implications
for therapy of allergic and autoimmune diseases. Ann Allergy
Asthma Immunol. 2003; 90(suppl. 3):34–40.
104. Aoishi K, Takahashi H, Hato N, et al. Treatment of allergic
rhinitis with intranasal infusion of botulinum toxin type A in
mice. Life Sci. 2016; 147:132–136.
105. Pal M, Angaru S, Kodimuthali A, and Dhingra N. Vanilloid
receptor antagonists: Emerging class of novel anti-inflamma-
tory agents for pain management. Curr Pharm Des. 2009;
15:1008–1026.
106. Dussor G, Yan J, Xie JY, et al. Targeting TRP channels for novel
migraine therapeutics. ACS Chem Neurosci. 2014; 5:1085–
1096. e
Allergy & Rhinology 9
